Aethlon Medical Inc (AEMD)

[philife]

I attend last night. Here is a quick bullet point run down about the different things that were cover:

1. ESI is going to be its own entity and any revenue that is made by the company will stay in the company to drive product research and development. However, it will be a plus for Aethlon on the balance sheet as the value of ESI will be reflect in the assets of AEMD.

2. They have big plans for assays that will be used for pharma clinical trials. These assays will be marketed to pharmas that will need assays to identify target populations as required by FDA's new regulations on drug development. I don't have all the information.

3. The NFL is back on... ESI is pursuing a grant with the NFL that will provide funding for an assay that they have developed that will be able to diagnosis a player with a potential concussion as soon as it is sustained on the field. The test currently doesn't have the capability to differentiate whether the player suffered the a brain injury as a result of the hit that they just took or if it was a hit that went undiagnosed the week before or you suffered a mini-stroke before the game. It will just be able to just say you have a brain injury, but it will be able to do so instantly. Dr. Taylor said he is confident that eventually they will be able to identify how the brain injury occurred. The NFL will be announcing the grants at this year's super bowl.

4. The first assay that will be marketed by ESI will be a HIV assay that is planned for launch in March 2014.

5. Dr. Taylor and his wife had 15+ patents on display that were very impressive. Two patents that caught my eye were Patents to use exosomes for viral vaccines and cancer vaccines. There were many others that were also very impressive, but these were the two that stuck to me.

6. Dr. Taylor seems to have his hands in every company that is on the forefront of exosome research. He helped Nanosight develop it's product along with many other companies.

7. They plan on rolling out their cancer assay by the end of 2014.


If I think of anything else I will post... Back to work.